SPG302 Reverses Synaptic and Cognitive Deficits Without Altering Amyloid or Tau Pathology in a Transgenic Model of Alzheimer’s Disease

Alzheimer’s disease (AD) is conceptualized as a synaptic failure disorder in which loss of glutamatergic synapses is a major driver of cognitive decline. Thus, novel therapeutic strategies aimed at regenerating synapses may represent a promising approach to mitigate cognitive deficits in AD patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Trujillo-Estrada, Laura, Vanderklish, Peter W., Nguyen, Marie Minh Thu, Kuang, Run Rong, Nguyen, Caroline, Huynh, Eric, da Cunha, Celia, Javonillo, Dominic Ibarra, Forner, Stefania, Martini, Alessandra C., Sarraf, Stella T., Simmon, Vincent F., Baglietto-Vargas, David, LaFerla, Frank M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804111/
https://www.ncbi.nlm.nih.gov/pubmed/34738197
http://dx.doi.org/10.1007/s13311-021-01143-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8804111/
https://www.ncbi.nlm.nih.gov/pubmed/34738197
http://dx.doi.org/10.1007/s13311-021-01143-1

Ejemplares similares